305 related articles for article (PubMed ID: 23842792)
1. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.
Jones LW; Fels DR; West M; Allen JD; Broadwater G; Barry WT; Wilke LG; Masko E; Douglas PS; Dash RC; Povsic TJ; Peppercorn J; Marcom PK; Blackwell KL; Kimmick G; Turkington TG; Dewhirst MW
Cancer Prev Res (Phila); 2013 Sep; 6(9):925-37. PubMed ID: 23842792
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.
Hornsby WE; Douglas PS; West MJ; Kenjale AA; Lane AR; Schwitzer ER; Ray KA; Herndon JE; Coan A; Gutierrez A; Hornsby KP; Hamilton E; Wilke LG; Kimmick GG; Peppercorn JM; Jones LW
Acta Oncol; 2014 Jan; 53(1):65-74. PubMed ID: 23957716
[TBL] [Abstract][Full Text] [Related]
3. High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.
Wang Y; Sparano JA; Fineberg S; Stead L; Sunkara J; Horwitz SB; McDaid HM
Clin Breast Cancer; 2013 Apr; 13(2):103-8. PubMed ID: 23218766
[TBL] [Abstract][Full Text] [Related]
4. Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Barros Filho MC; Katayama ML; Brentani H; Abreu AP; Barbosa EM; Oliveira CT; Góes JC; Brentani MM; Folgueira MA
Braz J Med Biol Res; 2010 Dec; 43(12):1225-31. PubMed ID: 21103787
[TBL] [Abstract][Full Text] [Related]
5. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Jones RL; Walsh G; Ashley S; Chua S; Agarwal R; O'Brien M; Johnston S; Smith IE
Br J Cancer; 2009 Jan; 100(2):305-10. PubMed ID: 19165198
[TBL] [Abstract][Full Text] [Related]
6. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Makhoul I; Griffin RJ; Siegel E; Lee J; Dhakal I; Raj V; Jamshidi-Parsian A; Klimberg S; Hutchins LF; Kadlubar S
Am J Clin Oncol; 2016 Jun; 39(3):248-54. PubMed ID: 24577164
[TBL] [Abstract][Full Text] [Related]
7. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.
Koike Folgueira MA; Brentani H; Carraro DM; De Camargo Barros Filho M; Hirata Katayama ML; Santana de Abreu AP; Mantovani Barbosa E; De Oliveira CT; Patrão DF; Mota LD; Netto MM; Caldeira JR; Brentani MM
Oncol Rep; 2009 Oct; 22(4):805-13. PubMed ID: 19724859
[TBL] [Abstract][Full Text] [Related]
9. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
[TBL] [Abstract][Full Text] [Related]
10. Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.
Prajoko YW; Aryandono T
Asian Pac J Cancer Prev; 2014; 15(2):595-8. PubMed ID: 24568463
[TBL] [Abstract][Full Text] [Related]
11. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
12. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Loibl S; von Minckwitz G; Raab G; Blohmer JU; Dan Costa S; Gerber B; Eidtmann H; Petrich S; Hilfrich J; Jackisch C; du Bois A; Kaufmann M
Ann Surg Oncol; 2006 Nov; 13(11):1434-42. PubMed ID: 16983592
[TBL] [Abstract][Full Text] [Related]
13. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
14. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
Cleator S; Tsimelzon A; Ashworth A; Dowsett M; Dexter T; Powles T; Hilsenbeck S; Wong H; Osborne CK; O'Connell P; Chang JC
Breast Cancer Res Treat; 2006 Feb; 95(3):229-33. PubMed ID: 16322899
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
Sánchez-Rovira P; Seguí MA; Llombart A; Aranda E; Antón A; Sánchez A; Lomas M; Jaén A; Fernández M; Porras I; Dalmau E; Morales S; de la Haba-Rodríguez J
Clin Transl Oncol; 2013 Oct; 15(10):810-7. PubMed ID: 23397155
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
Moon YW; Rha SY; Jeung HC; Yang WI; Suh CO; Chung HC
Ann Oncol; 2005 Nov; 16(11):1778-85. PubMed ID: 16091429
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
